There have been 50 recent insider transactions recorded for Madrigal Pharmaceuticals, Inc. (MDGL), including 20 buys and 27 sells. Total insider buying was valued at $37.6M and total insider selling at $8.97M.
Notable insiders with recent activity include Taub Rebecca, Sibold William John, Dier Mardi. Insider transactions can provide insights into how company leadership views the stock's valuation and future prospects.
Insider Transactions — MDGL
| Date |
Name |
Role |
Transaction |
Shares |
Avg. Price |
Value |
Shares Owned |
| 2026-03-06 |
Taub Rebecca |
Director |
Informative Sell |
491 |
$431.94 |
$212.08K |
452,213 |
| 2026-03-06 |
Sibold William John |
President and CEO |
Informative Sell |
1,663 |
$431.94 |
$718.32K |
161,829 |
| 2026-03-06 |
Dier Mardi |
EVP and CFO |
Informative Sell |
40 |
$437.65 |
$17.51K |
12,490 |
| 2026-03-06 |
Huntsman Carole |
Chief Commercial Officer |
Informative Sell |
419 |
$431.94 |
$180.98K |
12,692 |
| 2026-03-06 |
Kelley Shannon T |
General Counsel |
Informative Sell |
360 |
$431.94 |
$155.5K |
12,138 |
| 2026-03-04 |
Sibold William John |
President and CEO |
RSU Award |
18,743 |
$434.80 |
$8.15M |
18,743 |
| 2026-03-04 |
Dier Mardi |
EVP and CFO |
RSU Award |
6,519 |
$434.80 |
$2.83M |
6,519 |
| 2026-03-04 |
Soergel David |
Chief Medical Officer |
RSU Award |
5,467 |
$434.80 |
$2.38M |
5,467 |
| 2026-03-04 |
Huntsman Carole |
Chief Commercial Officer |
RSU Award |
4,986 |
$434.80 |
$2.17M |
4,986 |
| 2026-03-04 |
Kelley Shannon T |
General Counsel |
RSU Award |
5,022 |
$434.80 |
$2.18M |
5,022 |
| 2026-03-02 |
Dier Mardi |
EVP and CFO |
Informative Sell |
1,183 |
$427.21 |
$505.39K |
9,257 |
| 2026-02-23 |
Levy Richard S |
Director |
Option Exercise (Sell) |
2,500 |
$7.36 |
$18.4K |
- |
| 2026-01-26 |
Taub Rebecca |
Director |
Informative Sell |
647 |
$492.42 |
$318.6K |
452,704 |
| 2026-01-26 |
Levy Richard S |
Director |
Option Exercise (Sell) |
4,000 |
$16.46 |
$65.84K |
- |
| 2026-01-26 |
Sibold William John |
President and CEO |
Informative Sell |
1,577 |
$492.42 |
$776.55K |
148,497 |
| 2026-01-26 |
Huntsman Carole |
Chief Commercial Officer |
Informative Sell |
570 |
$494.59 |
$281.92K |
9,122 |
| 2026-01-20 |
Taub Rebecca |
Director |
Informative Sell |
2,238 |
$490.77 |
$1.1M |
453,351 |
| 2026-01-20 |
Kelley Shannon T |
General Counsel |
Informative Sell |
429 |
$501.40 |
$215.1K |
8,481 |
| 2026-01-15 |
Thakkar Rita |
Chief Accounting Officer |
RSU Award |
1,826 |
$495.88 |
$905.48K |
1,826 |
| 2026-01-12 |
Thakkar Rita |
Officer |
Unknown |
- |
- |
- |
- |
| 2026-01-09 |
Friedman Paul A |
Director |
Option Exercise (Sell) |
24,520 |
$15.80 |
$387.42K |
280 |
| 2026-01-09 |
Taub Rebecca |
Director |
Informative Sell |
271 |
$534.18 |
$144.76K |
457,242 |
| 2025-06-20 |
Bate Kenneth |
Director |
RSU Award |
1,290 |
$285.73 |
$368.59K |
1,290 |
| 2025-06-20 |
Friedman Paul A |
Director |
RSU Award |
1,290 |
$285.73 |
$368.59K |
1,290 |
| 2025-06-20 |
Baker Bros. Advisors Lp |
Director |
RSU Award |
2,580 |
$285.73 |
$737.18K |
2,580 |
| 2025-06-20 |
Fouse Jacqualyn A |
Director |
RSU Award |
366 |
$285.73 |
$104.58K |
366 |
| 2025-06-20 |
Levy Richard S |
Director |
RSU Award |
1,290 |
$285.73 |
$368.59K |
1,290 |
| 2025-06-20 |
Daly James M |
Director |
RSU Award |
1,290 |
$285.73 |
$368.59K |
1,290 |
| 2025-05-15 |
Soergel David |
Chief Medical Officer |
RSU Award |
7,545 |
- |
- |
7,545 |
| 2025-04-21 |
Soergel David |
Officer |
Unknown |
- |
- |
- |
- |
| 2025-03-13 |
Craves Fred B |
Director |
Option Exercise (Sell) |
7,742 |
$65.06 |
$503.69K |
- |
| 2025-03-12 |
Craves Fred B |
Director |
Option Exercise (Sell) |
6,000 |
$111.06 |
$666.36K |
- |
| 2025-03-10 |
Fouse Jacqualyn A |
Director |
Unknown |
- |
- |
- |
- |
| 2025-03-10 |
Fouse Jacqualyn A |
Director |
RSU Award |
894 |
- |
- |
894 |
| 2025-03-10 |
Dier Mardi |
SVP and CFO |
Informative Sell |
258 |
$323.04 |
$83.34K |
10,440 |
| 2025-03-05 |
Taub Rebecca |
Pres., R&d, and CMO |
RSU Award |
7,381 |
$347.28 |
$2.56M |
7,381 |
| 2025-03-05 |
Sibold William John |
President and CEO |
RSU Award |
22,009 |
$347.28 |
$7.64M |
22,009 |
| 2025-03-05 |
Dier Mardi |
SVP and CFO |
RSU Award |
6,374 |
$347.28 |
$2.21M |
6,374 |
| 2025-03-05 |
Waltermire Robert E. |
Senior VP, Chief Pharma Dev. |
RSU Award |
1,157 |
$347.28 |
$401.8K |
1,157 |
| 2025-03-05 |
Huntsman Carole |
Chief Commercial Officer |
RSU Award |
5,703 |
$347.28 |
$1.98M |
5,703 |
| 2025-03-05 |
Kelley Shannon T |
General Counsel |
RSU Award |
5,368 |
$347.28 |
$1.86M |
5,368 |
| 2025-03-03 |
Dier Mardi |
SVP and CFO |
Informative Sell |
774 |
$323.54 |
$250.42K |
6,914 |
| 2025-03-03 |
Huntsman Carole |
Chief Commercial Officer |
Informative Sell |
563 |
$335.00 |
$188.61K |
8,604 |
| 2025-03-03 |
Kelley Shannon T |
General Counsel |
Informative Sell |
415 |
$335.00 |
$139.03K |
7,290 |
| 2025-02-28 |
Waltermire Robert E. |
Senior VP, Chief Pharma Dev. |
Informative Sell |
175 |
$341.55 |
$59.77K |
3,728 |
| 2025-02-27 |
Bate Kenneth |
Director |
Option Exercise (Sell) |
9,470 |
$65.06 |
$616.12K |
- |
| 2025-02-27 |
Sibold William John |
President and CEO |
Option Exercise (Sell) |
50,000 |
- |
- |
- |
| 2025-02-27 |
Daly James M |
Director |
Option Exercise (Sell) |
9,470 |
$65.06 |
$616.12K |
- |
| 2025-01-24 |
Taub Rebecca |
Pres., R&d, and CMO |
Informative Sell |
648 |
$335.24 |
$217.24K |
456,662 |
| 2025-01-24 |
Sibold William John |
President and CEO |
Informative Sell |
1,584 |
$335.24 |
$531.02K |
54,303 |
■ Informative Buy/Sell — open market transaction (most significant)
■ Uninformative Buy — award, option exercise, conversion
■ Uninformative Sell — tax withholding, award vest sale
■ Neutral — gift, trust, expiry
